Market Overview

UPDATE: Piper Jaffray Initiates Inovio Pharmaceuticals at Overweight on DNA Vaccine Outlook

Related INO
Inovio Pharmaceuticals Expands HPV Immunotherapy Development To Aerodigestive Cancers
5 Companies Developing New Cancer Drugs

Piper Jaffray initiated coverage on Inovio Pharmaceuticals (NYSE: INO) with an Overweight rating and a $1.00 price target.

Piper Jaffray noted, "Inovio is developing a novel DNA-based vaccine platform, utilizing proprietary electroporation technology to create robust immune responses. Inovio's vaccines have demonstrated provocative immune responses in early studies against a multiple non-viral oncology targets (prostate, leukemia, breast, lung), as well as several infectious diseases HIV, HCV, HPV, and the flu. Based on earlier validation for producing uncommonly robust T-Cell responses, we are optimistic for the data expected in 4Q13, but note multiple Phase II catalysts expected this year in HCV and leukemia."

Inovio Pharmaceuticals closed at $0.67 on Thursday.

Latest Ratings for INO

DateFirmActionFromTo
Jul 2014Aegis CapitalUpgradesHoldBuy
May 2014Stifel NicolausInitiates Coverage onBuy
Nov 2013Aegis CapitalReiteratesHold

View More Analyst Ratings for INO
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (INO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters